Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/133261| Title: | Framework for pharmacist-led pharmacogenetics-guided proton pump inhibitor therapy |
| Authors: | Borg Gauci, Leanne Wirth, Francesca Azzopardi, Lilian M. |
| Keywords: | Pharmacogenetics Proton pump inhibitors Enzyme inhibitors Pharmacist and patient Gastroenterologists |
| Issue Date: | 2025 |
| Publisher: | Springer Nature Switzerland AG |
| Citation: | Borg Gauci, L., Wirth, F., & Azzopardi, L. M. (2025). Framework for pharmacist-led pharmacogenetics-guided proton pump inhibitor therapy. International Journal of Clinical Pharmacy. Retrieved from: doi: 10.1007/s11096-025-01891-6. |
| Abstract: | CYP2C19 is the principal enzyme involved in the metabolism of proton pump inhibitors (PPIs). CYP2C19 genetic polymorphisms impact response to PPIs, resulting in increased risk of therapy failure or tolerability issues. Implementation of pharmaco-genetics (PGx)-guided PPI therapy is still in its infancy. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/133261 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Framework_for_pharmacist_led_pharmacogenetics_guided_proton_pump_inhibitor_therapy_2025.pdf | 170.36 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.